Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen
Raya Aliakbar, Olga Manouvakhova, Cindy Wong, Myo Htut, Johannes Pulst‐Korenberg, Murali Janakiram, Michael Rosenzweig, Scott Goldsmith, Xenos Mason
Abstract
We report on a patient with ciltacabtagene autoleucel-induced movement and neurocognitive toxicity, which was refractory to immunosuppression but responsive to combination dopaminergic therapy (carbidopa/levodopa, ropinirole, amantadine). Response was seen upon both initial treatment and rechallenge after unintended withdrawal. This is the first report of a successful symptomatic treatment of this well-described neurotoxic syndrome.
Topics & Concepts
RopiniroleAmantadineMedicineParkinsonismDopaminergicRefractory (planetary science)CarbidopaLevodopaRegimenNeurocognitiveCombination therapyPharmacologyOncologyParkinson's diseaseInternal medicineDopamineDopamine agonistPsychiatryDiseaseAstrobiologyCognitionPhysicsCAR-T cell therapy researchBiomedical Ethics and Regulation